Scilex Holding (SCLX) Change in Account Payables (2022 - 2026)
Scilex Holding (SCLX) posted quarterly Change in Account Payables of $15.8 million for Q1 2026, up 208.35% year-over-year from $5.1 million in Q1 2025, and up 794.34% quarter-over-quarter from $1.8 million in Q4 2025.
Scilex Holding (SCLX) Change in Account Payables (2022 - 2026) Analysis & Trends
Scilex Holding's Change in Account Payables history runs 5 years deep, the most recent figure standing at $15.8 million for Q1 2026.
- In Q1 2026, Change in Account Payables rose 208.35% year-over-year to $15.8 million; the TTM figure through Mar 2026 stood at $23.8 million (up 111.0% YoY), while the FY2025 annual figure was $13.1 million, up 76.86% from the prior year.
- Change in Account Payables for Q1 2026 stood at $15.8 million, up from $1.8 million in the prior quarter.
- The five-year high for Change in Account Payables was $15.8 million in Q1 2026, with the low at -$612000.0 in Q2 2024.
- The 5-year median for Change in Account Payables is $2.0 million (2023), against an average of $3.5 million.
- The sharpest annual moves came in 2023 and 2024: Change in Account Payables jumped 5313.66% in 2023, then plunged 126.23% in 2024.
- Scilex Holding's Change in Account Payables stood at -$161000.0 in 2022, then surged by 5313.66% to $8.4 million in 2023, then tumbled by 38.61% to $5.2 million in 2024, then plunged by 65.69% to $1.8 million in 2025, then surged by 794.34% to $15.8 million in 2026.
- Business Quant data shows SCLX's Change in Account Payables at $15.8 million in Q1 2026, $1.8 million in Q4 2025, and $4.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -70.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 18.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Scilex Holding | 39.22 Mn | -73.57 Mn | 3.97 Mn | 3.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.81 Mn |
| Mar 31, 2026 | 15.81 Mn |
| Dec 31, 2025 | 1.77 Mn |
| Dec 31, 2025 | 1.77 Mn |
| Sep 30, 2025 | 4.50 Mn |
| Sep 30, 2025 | 4.50 Mn |
| Jun 30, 2025 | 1.73 Mn |
| Jun 30, 2025 | 1.73 Mn |
| Mar 31, 2025 | 5.13 Mn |
| Mar 31, 2025 | 5.13 Mn |
| Dec 31, 2024 | 5.15 Mn |
| Dec 31, 2024 | 5.15 Mn |
| Sep 30, 2024 | 1.61 Mn |
| Sep 30, 2024 | 1.61 Mn |
| Jun 30, 2024 | -612,000.00 |
| Jun 30, 2024 | -612,000.00 |
| Mar 31, 2024 | 1.27 Mn |
| Mar 31, 2024 | 1.27 Mn |
| Dec 31, 2023 | 8.39 Mn |
| Dec 31, 2023 | 8.39 Mn |